Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3133371
Max Phase: Preclinical
Molecular Formula: C61H87N15O17S4
Molecular Weight: 1430.72
Molecule Type: Protein
Associated Items:
ID: ALA3133371
Max Phase: Preclinical
Molecular Formula: C61H87N15O17S4
Molecular Weight: 1430.72
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(N)=O)CSSC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C61H87N15O17S4/c1-9-28(4)47-60(92)68-39(18-19-45(79)80)54(86)66-29(5)50(82)65-30(6)52(84)72-43-25-96-97-26-44(58(90)75-47)73-55(87)40(20-33-14-16-35(78)17-15-33)69-51(83)31(7)67-59(91)46(27(2)3)74-53(85)37(62)23-94-95-24-42(49(63)81)71-61(93)48(32(8)77)76-56(88)41(70-57(43)89)21-34-22-64-38-13-11-10-12-36(34)38/h10-17,22,27-32,37,39-44,46-48,64,77-78H,9,18-21,23-26,62H2,1-8H3,(H2,63,81)(H,65,82)(H,66,86)(H,67,91)(H,68,92)(H,69,83)(H,70,89)(H,71,93)(H,72,84)(H,73,87)(H,74,85)(H,75,90)(H,76,88)(H,79,80)/t28-,29-,30-,31-,32+,37-,39-,40-,41-,42-,43-,44-,46-,47-,48-/m0/s1
Standard InChI Key: YSPICSPDFZLOOE-IDBCTSBFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1430.72 | Molecular Weight (Monoisotopic): 1429.5287 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Meinander K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionpaa R, Widell K, Stenman U, Koistinen H, Narvanen A, Vepsalainen J, Luthman K, Wallen EAA. (2013) Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimetic stimulate kallikrein-related peptidase 3 activity, 4 (3): [10.1039/C3MD20292E] |
Source(1):